The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
By Josh Mailman Being a NET patient usually means some amount of travel for our care. While the pandemic has negatively impacted almost every aspect
Finding hope and motivation in a dark place, a young NET patient describes her life leading up and following peptide receptor radionuclide therapy (PRRT).
https://www.youtube.com/watch?v=k1906SABias The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor
PRRT Patients Tell Their Stories Following the early 2018 FDA approval of the first Peptide Receptor Radionuclide Therapy (PRRT) using lutetium Lu-177 dotatate, many people are
New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
NETRF in collaboration with NANETS awarded the 2017 Basic Translational Science Investigator grant to Brian R. Untch, M.D., at Memorial Sloan Kettering Cancer Center for his proposal, “Enhancing Peptide Receptor Radionuclide Therapy in Well-Differentiated Pancreatic Neuroendocrine Tumors.”
Peptide Receptor Radionuclide Therapy (PRRT) treats neuroendocrine tumors (NETs) by converting a cancer cell’s unique characteristics into a welcome mat for a Trojan Horse packed with cancer-killing radiation.
